J0219 Injection, avalglucosidase alfa-ngpt, 4 mg
Billable / valid for submission HCPCS Release 2026Q3
Short description: Inj aval alfa-nqpt 4mg
Version history
| Release | Valid from | Valid to | Description | Billable |
|---|---|---|---|---|
| 2026Q3 | 2026-07-01 | current | Injection, avalglucosidase alfa-ngpt, 4 mg | yes |
Related codes in J02
- J0202 Injection, alemtuzumab, 1 mg
- J0206 Injection, allopurinol sodium, 1 mg
- J0207 Injection, amifostine, 500 mg
- J0208 Injection, sodium thiosulfate (pedmark), 100 mg
- J0209 Injection, sodium thiosulfate (hope), 100 mg
- J0210 Injection, methyldopate hcl, up to 250 mg
- J0211 Injection, sodium nitrite 3 mg and sodium thiosulfate 125 mg (nithiodote)
- J0216 Injection, alfentanil hydrochloride, 500 micrograms
- J0217 Injection, velmanase alfa-tycv, 1 mg
- J0218 Injection, olipudase alfa-rpcp, 1 mg
- J0220 Injection, alglucosidase alfa, 10 mg, not otherwise specified
- J0221 Injection, alglucosidase alfa, (lumizyme), 10 mg
- J0222 Injection, patisiran, 0.1 mg
- J0223 Injection, givosiran, 0.5 mg
- J0224 Injection, lumasiran, 0.5 mg
- J0225 Injection, vutrisiran, 1 mg
- J0248 Injection, remdesivir, 1 mg
- J0256 Injection, alpha 1 proteinase inhibitor (human), not otherwise specified, 10 mg
- J0257 Injection, alpha 1 proteinase inhibitor (human), (glassia), 10 mg
- J0270 Injection, alprostadil, 1.25 mcg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)